Boehringer Ingelheim's new 120 million euro Investment in Greece
- Written by E.Tsiliopoulos
The research-driven biopharmaceutical company Boehringer Ingelheim announced that it will invest 120 million euros to expand and upgrade its plant in Greece.
In a press release on Thursday, the company explained that the Greece-based investment is slotted for its existing plant in Koropi, which is located in the Attica region.
The funds will enable the plant to increase the manufacturing capacity of the plant in regards to new and existing medications and will add 110 new jobs.
Some of the key disease areas addressed by the medications produced by the plant include cardio-renal-metabolic (CRM) diseases, mental health and pulmonary fibrosis.
Exports of a well-known drug for type 2 diabetes, heart failure and chronic kidney disease called Jardiance will be enhanced and sent to the USA.
The ceremony where the announcement was made was attended by Greek Prime Minister Kyriakos Mitsotakis, Greek Minster of State, the Minister of Health and the Minister of Development.
Related items
- Holy Wednesday tragedy: Car hits five - three children
- Lone black swan spotted in Evros
- Greek police release the details of 8 people accused of homicide and arson
- Deputy FM Kotsiras: Bringing young college students and researchers of the diaspora closer to Greece
- Visa express now available on five more Greek islands for Turkish citizens
Latest from E.Tsiliopoulos
- Holy Wednesday tragedy: Car hits five - three children
- Lone black swan spotted in Evros
- Greek police release the details of 8 people accused of homicide and arson
- Deputy FM Kotsiras: Bringing young college students and researchers of the diaspora closer to Greece
- Visa express now available on five more Greek islands for Turkish citizens